• Clear Cell (ovarian only, no primary peritoneal or fallopian tube) First Line (1 trial)

  • Temsirolimus + Carboplatin/Paclitaxel Stage III-IV Clear Cell Carcinoma of the Ovary (GOG-0268)
    A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC#683864, IND#61010) in Combination with Carboplatin and Paclitaxel followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary

• Paclitaxel vs Polyglutamate Paclitaxel (GOG 212)
  A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
• Vaccine Therapy for Stage III-IV Ovarian Cancer (7396)
  A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients With Advanced Ovarian Cancer

• Carboplatin + Paclitaxel w/wo Bevacizumab After Surgery (GOG 213)
  A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination With Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreduction Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
• PARP Inhibitor ABT-888 with Carboplatin & Gemcitabline (M10-758) (UW09039)
  A Phase 1 Study of ABT-888 (Veliparib) in Combination With Carboplatin (Paraplatin) and Gemcitabline (Gemzar) in Subjects With Advanced Solid Tumors
• EP-100 Plus Paclitaxel Versus Paclitaxel Alone for Ovarian Cancer (7685)
  EP-100, a Novel LHRH Receptor-Targeted Membrane-Disruptive Peptide, plus PaclitaxelÆ versus PaclitaxelÆ alone for Refractory or Recurrent Ovarian Cancer: a Phase II, Randomized, Multi-Center Trial
• Paclitaxel With or Without Pazopanib in Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (GOG 186-J)
  A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) (IND #75648) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

• EP-100 Plus Paclitaxel Versus Paclitaxel Alone for Ovarian Cancer (7685)
  EP-100, a Novel LHRH Receptor-Targeted Membrane-Disruptive Peptide, plus PaclitaxelÆ versus PaclitaxelÆ alone for Refractory or Recurrent Ovarian Cancer: a Phase II, Randomized, Multi-Center Trial
• Paclitaxel With or Without Pazopanib in Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (GOG 186-J)
  A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) (IND #75648) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
• MDX-1105 for Advanced or Recurrent Cancer (UW08038)
  A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors

• EC145 in Combination With DoxilÆ for Platinum Resistant Ovarian Cancer (7334)
  Protocol EC-FV-06: A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (Pld/DoxilÆ/CaelyxÆ) In Combination Versus PLD In Participants with Platinum-Resistant Ovarian Cancer
• EP-100 Plus Paclitaxel Versus Paclitaxel Alone for Ovarian Cancer (7685)
  EP-100, a Novel LHRH Receptor-Targeted Membrane-Disruptive Peptide, plus PaclitaxelÆ versus PaclitaxelÆ alone for Refractory or Recurrent Ovarian Cancer: a Phase II, Randomized, Multi-Center Trial
• MLN8237, an Aurora A Kinase Inhibitor w/ Weekly Paclitaxel (C14008)(UW09039)
  Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer
• Paclitaxel With or Without Pazopanib in Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (GOG 186-J)
  A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) (IND #75648) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
• MDX-1105 for Advanced or Recurrent Cancer (UW08038)
  A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors

• Paclitaxel + Carboplatin vs Ifosfamide + Paclitaxel for Uterine or Ovarian Cancer (GOG 0261)
  A Randomized Phase III Trial of Paclitaxel plus Carboplatin versus Ifosfamide plus Paclitaxel in Chemotherapy-NaÔve Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary

Trials pending. None currently open.

• Combination Chemotherapy + Radiation Therapy for Stage III/IVA Endometrial Cancer (GOG 0258)
  A Randomized Phase III Trial of Cisplatin and Tumor Volume Directional Irradiation Followed By Carboplatin and Paclitaxel Vs.for Optimally Debulked, Advanced Endometrial Carcinoma

• Dalantercept for Recurrent or Persistent Endometrial Cancer (GOG-299N)
  A Phase II Evaluation of Dalantercept, A Novel Soluable Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in Treatment of Recurrent or Persistent Endometrial Carcinoma
• BIBF 1120 in Recurrent or Persistent Endometrial Cancer (GOG 229-K)
  A Phase II Evaluation of BIBF 1120 (IND #) in the Treatment of Recurrent or Persistent Endometrial Carcinoma

• Chemotherapy + Pelvic Radiation for High-Risk Early-Stage Cervical Cancer (GOG/ RTOG 0724)
  Chemotherapy + Pelvic Radiation for High-Risk Early-Stage Cervical Cancer (GOG/ RTOG 0724) Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

• Veliparib (ABT-888) + Chemotherapy for Recurrent Cervical Cancer (GOG 0127W)
  A Phase II Evaluation of ABT-888, (IND# 77840, NCI Supplied Agent: NSC #737664) Topotecan (NSC # 609699), and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix

• FDG PET for Advanced Ovarian Cancer (FHCRC-7009)
  Neo-Adjuvant Imaging FDG PET and Biomarkers in Treatment Response in Advanced Ovarian Cancer
• Memory and Thinking Skills Workshop in Improving Cognitive Rehabilitation in Ovarian Cancer Survivors (7750)
  Behavioral and Neural Indices of Cognitive Rehabilitation in Ovarian Cancer: A Pilot Study